Xenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with Chemotherapy

January 17, 2023 8:05 AM

FRAMINGHAM, MA / ACCESSWIRE / January 17, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance for Patent Application No. 3,001,543 titled, "Method to Improve Safety and Efficacy of...

Read more

TISSIUM Appoints Alex Milstein as Chief Medical Officer

January 17, 2023 3:00 AM

PARIS, FRANCE and BOSTON, MA / ACCESSWIRE / January 17, 2023 / TISSIUM, a privately-owned medical technology company developing a portfolio of biomorphic programmable polymers for tissue reconstruction, announced today it has appointed Dr. Alex Milstein as its Chief Medical Officer.The addition of Dr. Milstein to TISSIUM's executive leadership team is reflective of the company's continued focus on platform expansion, generation of clinical...

Read more

Core One Labs' Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers

January 13, 2023 7:25 PM

VANCOUVER, BC / ACCESSWIRE / January 13, 2023 / Core One Labs Inc. (CSE:COOL)(OTCQB:CLABF)(Frankfurt:LD6)(WKN: A3CSSU) (the "Company" or "Core One"), is pleased to announce that it has acquired (the "Acquisition") GMP Drug Inc. ("GMP Drug"), an arms-length privately held company that operates through a Good Manufacturing Practices ("GMP") facility (the "Facility") owned by a third-party located in Ontario, Canada. The Acquisition will lay the...

Read more

Lexaria Releases Annual Letter from the CEO

January 13, 2023 4:05 PM

KELOWNA, BC / ACCESSWIRE / January 13, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide an annual letter from CEO, Chris Bunka and a thorough strategic update to all stakeholders.CEO LETTER TO STAKEHOLDERSAs 2022 came to a close, it isn't news that nearly all companies - not to mention most people - are facing challenges not experienced...

Read more

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

January 12, 2023 2:00 AM

Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent GlioblastomaABINGDON, UK / ACCESSWIRE / January 12, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that following completion of one month of treatment with MTX-110 in the first patient, its Phase I study of MTX-110 in...

Read more

Pieris Pharmaceuticals Announces $5 Million Milestone from Seagen for Initiation of Phase 1 Trial of CD228 x 4-1BB Bispecific Molecule (Mabcalin SGN-BB228 (PRS-346)

January 10, 2023 8:00 AM

BOSTON, MA / ACCESSWIRE / January 10, 2023 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other conditions, today announced that the Company has achieved a $5 million milestone from Seagen. The milestone is based on dosing the first patient in a Seagen-sponsored phase 1 study of...

Read more

Nascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial

January 10, 2023 8:00 AM

NORTH PALM BEACH, FL / ACCESSWIRE / January 10, 2023 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company pioneering the development of monoclonal antibodies targeting various cancer types, announced today the completion and closure of enrollment for the final cohort of patients involved in the Company's Phase I trial to evaluate Pritumumab ("PTB") as a treatment for Brain...

Read more

Midatech Pharma PLC Announces Posting of Circular and Notice of General Meeting

January 6, 2023 2:00 AM

Posting of Circular Regarding Proposed Acquisition of Bioasis, Equity Raise of US$9.6 million, Change of Name and Notice of General MeetingABINGDON, UK / ACCESSWIRE / January 6, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces, further to the Company's announcements of 13 December and 19 December 2022, that a circular (the...

Read more

NovAccess Global Announces Fireside Chat with Dr. Christopher Wheeler, the Company’s Lead Scientist and President of its StemVax Therapeutics Division

January 5, 2023 12:15 PM

Topic: Immunotherapy Advantages Over Surgical TreatmentCLEVELAND, OH / ACCESSWIRE / January 5, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, today announced the availability of its latest monthly installment in a series of fireside chat interviews, with additional sessions to be made available as company developments arise. Interviews are intended to cover important and...

Read more

Xenetic Biosciences, Inc. to Present at the Virtual Investor 2023 Companies to Watch Event

January 5, 2023 8:05 AM

Live video webcast on Tuesday, January 17th at 10:00 AM ETFRAMINGHAM, MA / ACCESSWIRE / January 5, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences will present at the Virtual Investor 2023...

Read more

Plandai Biotechnologies, Inc. Announces Termination of Asset Acquisition Agreement with EV Hotel, Updates on Status of Independent Audit

January 4, 2023 7:00 AM

SAN DIEGO, CA / ACCESSWIRE / January 4, 2023 / (OTC:PLPL) Plandai Biotechnology, Inc. ("Plandai" or the "Company") announces the termination of its previously announced asset acquisition agreement with EV Hotel Corp., a Georgia corporation. The termination was agreed to by both parties, and the Company incurred no penalties, costs, or liabilities in connection with the termination.The Company completed its two-year independent audit of its...

Read more

EV Biologics Updates on Excyte Subsidiary Funding

January 3, 2023 8:30 AM

TAMPA, FL / ACCESSWIRE / January 3, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has now closed $1,000,000 of its $2.5 million initial capitalization goal.One hundred thousand shares (100,000) have been issued at $10 per share, out of a total issuance of ten million shares to EV Biologics. Excyte, a wholly owned subsidiary, was launched in August 2022, with $100 Million valuation. The Company aims to close the balance of the...

Read more

Lexaria's DehydraTECH-CBD Achieves Superior Human Blood Absorption Levels

December 21, 2022 9:00 AM

KELOWNA, BC / ACCESSWIRE / December 21, 2022/ Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has demonstrated superior cannabidiol ("CBD") blood absorption levels from its patented DehydraTECH-CBD™ relative to those of published, pharmaceutical-grade CBD industry comparators in its recently completed, multi-week human clinical hypertension...

Read more

Lexaria’s Human Oral Nicotine Study Begins Dosing

December 20, 2022 12:35 PM

Lexaria's DehydraTECH-nicotine pouch performance to be compared to existing leading brands ON! and ZynKELOWNA, BC / ACCESSWIRE / December 20, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce that dosing has now begun in its human clinical nicotine study NIC-H22-1.Study NIC-H22-1 is a 36-person human pharmacokinetic randomized, double...

Read more

FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate

December 20, 2022 8:30 AM

Fast Track improves the speed and frequency of communication with FDA, potentially leading to earlier drug approval and access by patients.TORONTO, ON / ACCESSWIRE / December 20, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, has received Fast Track designation from the U.S. Food and Drug Administration for its monoclonal antibody candidate, EB05. Approval...

Read more

Nascent Biotech Announces Appointment of Dr. Ivan Babic to Scientific Advisory Board

December 20, 2022 8:00 AM

VERO BEACH, FL / ACCESSWIRE / December 20, 2022 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting the treatment of various cancers, announced today that Dr. Ivan Babic, a renowned cancer expert, has been appointed to the Company's scientific advisory board.Dr. Babic is currently the Director of Gilman Biosciences. With more than...

Read more

BioInvent Initiates Phase 1 Trial with Subcutaneous Formulation of BI-1206

December 19, 2022 7:10 AM

LUND, SE / ACCESSWIRE / December 19, 2022 / BioInvent International (STO:BINV)Starting dose predicted to provide drug exposure at levels already shown to have elicited responsesSubcutaneous formulation is significantly more convenient administration for patientsBioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory...

Read more

Enzolytics, Inc. Announces the Completion of the 2020 and 2021 Audited Financials

December 19, 2022 7:00 AM

COLLEGE STATION, TX / ACCESSWIRE / December 19, 2022 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com/).Enzolytics, Inc. announces the completion of the 12/31/2020 and 12/31/2021 audited financials. The Company has refiled the 12/31/2021 Disclosure Statement reflecting the completion of the audit covering 2020 and 2021. These filings provide investors with detailed audited information about the Company's operations, business...

Read more

BioInvent Receives Notice of Allowance in the US for Patent Covering BI-1206 and BI-1607

December 19, 2022 6:00 AM

LUND, SE / ACCESSWIRE / December 19, 2022 / BioInvent International (STO:BINV)Lund, Sweden - December 19, 2022 - BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance,...

Read more

Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2023

December 19, 2022 4:45 AM

LUND, SWEDEN / ACCESSWIRE / December 19, 2022 / BioInvent International (STO:BINV) Lund, Sweden - December 19, 2022 - The members of the Nomination Committee for BioInvent International AB:s (publ) ("BioInvent) Annual General Meeting in 2023 have now been appointed.The following representatives of BioInvent International AB's shareholders will be members of the Nomination Committee for the Annual General Meeting 2023:Laura Feinleib, appointed by...

Read more